Clinical trials: Prevention of Thromboembolic Events
Venous Thromboembolism
A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin The secondary objectives of the…
- Trial name
- NCT05618808
- Testing
- REGN9933, Enoxaparin, Apixiban
- Where
- 16 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 373 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism, Multiple Myeloma
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs).
- Trial name
- NCT02958969
- Testing
- Apixaban
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gregory Piazza
End-stage Renal Disease, Prevention of Thromboembolic Events
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
In this study researchers want to learn about the safety of drug Osocimab at lower-dose and higher-doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins…
- Conditions
- End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
- Trial name
- CONVERT (NCT04523220)
- Testing
- BAY1213790 (Osocimab)
- Where
- 151 sites in United States, Australia and 17 more
- Volunteers
- 704 people
- Sponsor
- Bayer
Blood Clot, Trauma
PREVENTion of Clot in Orthopaedic Trauma
The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.
- Trial name
- PREVENT CLOT (NCT02984384)
- Testing
- Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH)
- Where
- 21 sites in United States, Canada
- Volunteers
- 12,424 people
- Sponsor
- Major Extremity Trauma Research Consortium
Thromboembolism, Arthroplasty, Replacement, Hip
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Open, prospective, uncontrolled, observational cohort study.
- Trial name
- NCT00967447
- Where
- 28 sites in Mexico
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03080883
- Testing
- Apixaban
- Where
- 32 sites in United States
- Volunteers
- 370 people
- Sponsor
- Academic and Community Cancer Research United
Venous Thromboembolism, Pulmonary Embolism
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening.
- Trial name
- PHACS (NCT00876915)
- Testing
- dalteparin injection
- Where
- 7 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- University of Rochester
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
The objective of this study is to evaluate the safety and efficacy of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective hip fracture surgery.
- Trial name
- NCT01181141
- Testing
- DU-176b (edoxaban), Enoxaparin sodium 20mg
- Where
- Japan
- Volunteers
- 92 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Major Orthopaedic Surgery and Renal Impairment
Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.
Fondaparinux is an antithrombotic agent having already received a regulatory approval by the European Authorities in venous thromboembolic event prevention after major orthopaedic surgery, as total hip replacement (THR), total…
- Trial name
- PROPICE (NCT00555438)
- Testing
- fondaparinux 1.5 mg/day
- Where
- 29 sites in France
- Volunteers
- 451 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
COVID-19, Venous Thromboembolism
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
The researchers wanted to learn how to help sick patients who are in the hospital because of COVID-19. They are trying to find out the best way that is safe to stop blood clots that could be dangerous from forming in patients…
- Conditions
- COVID-19, Venous Thromboembolism, Arterial Thrombosis
- Trial name
- COVID-PACT (NCT04409834)
- Testing
- Unfractionated Heparin IV, Enoxaparin 1 mg/kg, Clopidogrel
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- The TIMI Study Group
Venous Thromboembolism, Ovarian Cancer
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.
- Trial name
- NCT04352439
- Testing
- Aspirin
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Duke University
Venous Thromboembolism, Arthroplasty, Replacement
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
an open, prospective, observational study to collect data on safety (major bleeding events) and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to dabigatran etexilate in patients with total knee…
- Trial name
- NCT01153698
- Testing
- dabigatran
- Where
- 7 sites in Austria
- Volunteers
- 167 people
- Sponsor
- Boehringer Ingelheim
Deep Venous Thrombosis
Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial
The purpose of this phase 2a, multi-center, randomized controlled study, is to explore the efficacy of early prophylaxis against catheter-associated deep venous thrombosis (CADVT) in critically ill children.
- Trial name
- CRETE (NCT03003390)
- Testing
- Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Yale University
Venous Thromboembolism, Deep Vein Thrombosis
OsciPulse Device for the Prevention of VTE
This is a Phase 2 safety and tolerability trial that will take place in two parts. Part one of the trial will determine the tolerability of the OsciPulse device on healthy subjects who wear the device for up to three hours.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Thromboembolisms
- Trial name
- NCT04625673
- Testing
- OsciPulse
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Arthroplasty, Replacement, Knee, Thromboembolism
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the ef ficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule s [150 or 220 mg once daily…
- Trial name
- NCT00168805
- Testing
- enoxaparin, dabigatran etexilate
- Where
- 105 sites in Australia, Austria and 13 more
- Volunteers
- 2,101 people
- Sponsor
- Boehringer Ingelheim